News & Announcements

May 2023

FDA advisory committee votes unanimously to recommend Opill for over-the-counter use

May 10, 2023 – Today, in a landmark step for reproductive health, a joint FDA advisory committee voted unanimously to allow a birth control pill to be offered over the counter (OTC). The advisory committee vote reflects the decades of science showing that birth control pills are safe and...
May 2023

Regina Tamés and Jay Zussman join Ibis Board of Directors; Fatimah Gifford starts term as Board Chair

We are thrilled to announce that Regina Tamés and Jay Zussman have joined the Ibis Board of Directors as Members at Large, and Fatimah Gifford is starting her term as Board Chair. Fatimah will be building on the work of former Board Chair Thoai Ngo to continue to advance racial justice and...
April 2023

Ibis responds to federal court decisions on mifepristone registration and availability

Cambridge, MA, April 10, 2023 – On Friday, April 7, 2023, a judge in a Texas federal court released a ruling in Alliance for Hippocratic Medicine v. FDA. The ruling places a stay on the FDA’s approval of mifepristone and seeks to remove it from the market nationwide. The same day...
March 2023

AMAZE Africa media event amplified sexuality education in Sub-Saharan Africa

Insights from the World Population Review indicate that over 13 million children are born to women who are under 20 years old. Disturbingly, more than 90% of these births (about 12 million) occur in developing countries, with African countries topping the list. To address high rates of teenage...
March 2023

Exciting new partnership will advance comprehensive sexuality education in sub-Saharan Africa

Ibis Reproductive Health South Africa is proud to announce its partnership with Advocates For Youth (AFY) as the new Sub-Saharan Africa regional lead for the AMAZE Africa initiative, with the intention of amplifying ongoing efforts in the region to make comprehensive sexuality education resources...
March 2023

FDA schedules advisory committee meeting for over-the-counter birth control pill to take place May 9-10

The FDA announced today that an advisory committee meeting is scheduled for May 9 and 10 to review the first-ever application for an over-the-counter birth control pill. In July 2022, HRA Pharma announced it had submitted this application to the FDA to switch Opill, a progestin-only, daily birth...